SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Relationship Between Blood Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian Randomization Analyses.

Malik, R; Georgakis, MK; Vujkovic, M; Damrauer, SM; Elliott, P; Karhunen, V; Giontella, A; Fava, C; Hellwege, JN; Shuey, MM; et al. Malik, R; Georgakis, MK; Vujkovic, M; Damrauer, SM; Elliott, P; Karhunen, V; Giontella, A; Fava, C; Hellwege, JN; Shuey, MM; Edwards, TL; Rogne, T; Åsvold, BO; Brumpton, BM; Burgess, S; Dichgans, M; Gill, D (2021) Relationship Between Blood Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian Randomization Analyses. Hypertension, 77 (6). pp. 2004-2013. ISSN 1524-4563 https://doi.org/10.1161/HYPERTENSIONAHA.120.16534
SGUL Authors: Gill, Dipender Preet Singh

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Observational studies exploring whether there is a nonlinear effect of blood pressure on cardiovascular disease (CVD) risk are hindered by confounding. This limitation can be overcome by leveraging randomly allocated genetic variants in nonlinear Mendelian randomization analyses. Based on their association with blood pressure traits in a genome-wide association study of 299 024 European ancestry individuals, we selected 253 genetic variants to proxy the effect of modifying systolic and diastolic blood pressure. Considering the outcomes of incident coronary artery disease, stroke and the combined outcome of CVD, linear and nonlinear Mendelian randomization analyses were performed on 255 714 European ancestry participants without a history of CVD or antihypertensive medication use. There was no evidence favoring nonlinear relationships of genetically proxied systolic and diastolic blood pressure with the cardiovascular outcomes over linear relationships. For every 10-mm Hg increase in genetically proxied systolic blood pressure, risk of incident CVD increased by 49% (hazard ratio, 1.49 [95% CI, 1.38-1.61]), with similar estimates obtained for coronary artery disease (hazard ratio, 1.50 [95% CI, 1.38-1.63]) and stroke (hazard ratio, 1.44 [95% CI, 1.22-1.70]). Genetically proxied blood pressure had a similar relationship with CVD in men and women. These findings provide evidence to support that even for individuals who do not have elevated blood pressure, public health interventions achieving persistent blood pressure reduction will be of considerable benefit in the primary prevention of CVD.

Item Type: Article
Additional Information: © 2021 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Keywords: blood pressure, coronary artery disease, hypertension, primary prevention, stroke, Cardiovascular System & Hematology, 1103 Clinical Sciences, 1102 Cardiorespiratory Medicine and Haematology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Hypertension
ISSN: 1524-4563
Language: eng
Dates:
DateEvent
June 2021Published
5 April 2021Published Online
16 February 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
IK2-CX001780U.S. Department of Veterans Affairshttp://dx.doi.org/10.13039/100000738
RE/18/4/34215British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
MR/S019669/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
1004231Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
DK108444National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
204623/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
666881Horizon 2020UNSPECIFIED
203928/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
RE/18/4/34215British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
CL-2020-16-001National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
S10RR025141National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
UL1TR002243National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
UL1TR000445National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
UL1RR024975National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
U01HG004798National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
R01NS032830National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
RC2GM092618National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
P50GM115305National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
U01HG006378National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
U19HL065962National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
R01HD074711National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
PubMed ID: 33813844
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113139
Publisher's version: https://doi.org/10.1161/HYPERTENSIONAHA.120.16534

Actions (login required)

Edit Item Edit Item